1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Johnson & Johnson

Johnson & Johnson

JNJ.TO
Johnson & JohnsonCA flagToronto Stock Exchange
34.56
CAD
+0.23
- -
856.70BMarket Cap
Johnson & Johnson
JNJ.TO
(Toronto Stock Exchange)

Recent

price

34.56

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.19
2.32
2.35
2.46
2.6
2.47
2.58
2.77
2.98
3.03
3.05
2.91
2.98
3.27
3.59
3.8
3.95
Revenue per Share
0.47
0.35
0.38
0.48
0.57
0.54
0.59
0.05
0.56
0.56
0.54
0.77
0.67
1.35
0.57
1.08
0.85
Basic EPS, GAAP
0.5
0.41
0.44
0.48
0.52
0.57
0.56
0.64
0.68
0.74
0.75
0.73
0.64
0.68
0.73
0.78
0.9
Free Cash Flow per Basic Share
0.21
0.22
0.23
0.25
0.27
0.29
0.31
0.32
0.35
0.37
0.39
0.41
0.43
0.45
0.48
0.5
0.51
Dividend per Share
20.66
20.95
23.33
26.25
25.06
25.82
26.02
22.43
22.44
22.59
24.04
28.16
29.39
28.57
29.7
33.86
35.28
Book Value per Share
8.97
8.37
4.91
8.26
7.44
8.62
7.66
-9.31
-6.88
-8.29
-10.07
-2.9
0.87
-0.81
-4.29
-7.32
-4.87
Tangible Book Value per Share
28,165
28,024
28,580
29,014
28,629
28,340
27,840
27,593
27,385
27,079
27,079
27,042
26,884
26,060
24,758
24,763
24,770
Basic Weighted Avg Shares
61,587
65,030
67,224
71,312
74,331
70,074
71,890
76,450
81,581
82,059
82,584
78,740
79,990
85,159
88,821
94,193
97,929
Sales/Revenue/Turnover
26.84
24.84
25.34
26.58
28.44
26.1
29.06
24.72
25.96
25.55
24.11
26.6
26.27
25.84
23.92
27.17
26.81
Operating Margin (%)
2,939
3,158
3,666
4,104
3,895
3,746
3,754
5,642
6,929
7,009
7,231
7,390
6,970
7,486
7,339
7,503
7,751
Depreciation Expense
13,334
9,672
10,853
13,831
16,323
15,409
16,540
1,300
15,297
15,119
14,714
20,878
17,941
35,153
14,066
26,804
21,037
Net Income, GAAP
21.32
21.75
23.67
10.6
20.62
19.73
16.48
92.64
15.01
12.75
10.81
7.18
15.44
11.53
15.71
17.73
16.51
Effective Tax Rate (%)
21.65
14.87
16.14
19.4
21.96
21.99
23.01
1.7
18.75
18.42
17.82
26.52
22.43
41.28
15.84
28.46
21.48
Profit Margin (%)
24,235
31,505
21,854
30,732
30,713
32,463
38,745
12,551
14,803
9,310
8,744
15,753
-508
7,213
5,572
1,498
4,879
Working Capital
9,156
12,969
11,489
13,328
15,122
12,857
22,442
30,675
27,684
26,494
32,635
29,985
26,886
25,881
30,651
39,438
37,344
LT Debt
56,579
57,080
64,826
74,053
69,752
71,150
70,418
60,160
59,752
59,471
63,278
74,023
76,804
68,774
71,490
81,544
84,971
Total Equity
18.73
16.76
16.37
19.45
18.5
16.3
18.39
1.43
19.24
20.33
18.81
18.66
15.64
17.75
16.84
17.37
16.51
Return on Invested Capital (%)
19.77
13.49
14.71
16.47
18.53
17.66
18.19
1.42
17.46
17.36
16.04
20.4
16.21
33.41
14.26
23.23
16.63
Return on Capital (%)
24.88
17.02
17.81
19.92
22.7
21.87
23.37
1.99
25.51
25.36
23.97
30.41
23.79
48.29
20.06
35.03
25.74
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,495
17,460
11,692
LT Borrowings
39,438
37,527
37,344
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,408
2,407
2,408
Market Capitalization
47,116
54,499
55,463

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,624
59,173
59,774
Cash, Cash Equivalents & STI
20,102
22,051
20,758
Accounts Receivable, Net
17,178
17,721
19,046
Inventories
14,191
14,583
15,144
Total Current Liabilities
54,126
57,716
54,895
Payables & Accruals
41,097
37,345
39,728
ST Debt
8,495
17,460
11,692
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.79%
5.66%
14.06%
Free Cash Flow
2.08%
-0.64%
6.94%
Net Income, GAAP
114.24%
30.87%
90.56%
Sales/Revenue/Turnover
3.06%
2.75%
6.05%
Total Cash Common Dividend
4.26%
3.41%
4.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
21,383
22,447
22,471
22,520
88,821
2025
21,893
23,743
23,993
24,564
94,193
2026
24,062
25,310
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.19
0.11
0.14
0.57
2025
0.44
0.22
0.21
0.21
1.08
2026
0.21
0.22
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.12
0.12
0.12
0.48
2025
0.12
0.13
0.13
0.13
0.5
2026
0.13
0.13
- -
- -
- -
Similar Companies
NGL Fine-Chem Limited (NGLFINE.NS)
GSK plc (GSK)
Bristol-Myers Squibb Company (BMY.SW)
AstraZeneca PLC (ZEG.DE)
Merck & Co., Inc. (MRK.PA)
Orion Oyj (ORINY)
Business
Johnson & Johnson is a global healthcare company that researches, develops, manufactures and markets a broad portfolio of prescription medicines and medical technologies through its Innovative Medicine and MedTech segments; its products and services include oncology, immunology, neuroscience, cardiovascular and metabolic disease, pulmonary hypertension, and retina therapies, as well as surgical technologies, orthopaedics, interventional solutions, vision care, electrophysiology, and connected care offerings. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, and operates worldwide across the United States, Europe, Asia-Pacific, Latin America and other international markets, serving patients, healthcare professionals, hospitals and health systems. In recent periods, Johnson & Johnson has accelerated portfolio expansion through acquisitions and strategic alliances, including the acquisition of Firefly Bio to strengthen its oncology pipeline; a strategic partnership and exclusive option to acquire Sail Biomedicines for in vivo CAR-T and autoimmune disease therapies; and the acquisition of Halda Therapeutics, adding its RIPTAC platform and clinical-stage oncology candidates to the company’s research pipeline. The company also continues to advance product innovation and commercial expansion, including approvals and submissions across oncology and other therapeutic areas, while maintaining a focus on less invasive, more personalized treatments and next-generation medtech systems.